These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9433426)

  • 21. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme.
    Wright AD; Dodson PM
    Eye (Lond); 2010 Jan; 24(1):1-6. PubMed ID: 19648902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
    Chaturvedi N; Porta M; Klein R; Orchard T; Fuller J; Parving HH; Bilous R; Sjølie AK;
    Lancet; 2008 Oct; 372(9647):1394-402. PubMed ID: 18823656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
    Mogensen CE; Neldam S; Tikkanen I; Oren S; Viskoper R; Watts RW; Cooper ME
    BMJ; 2000 Dec; 321(7274):1440-4. PubMed ID: 11110735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy.
    Tarnow L; Sato A; Ali S; Rossing P; Nielsen FS; Parving HH
    Diabetes Care; 1999 Mar; 22(3):491-4. PubMed ID: 10097934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
    Sjølie AK; Klein R; Porta M; Orchard T; Fuller J; Parving HH; Bilous R; Chaturvedi N;
    Lancet; 2008 Oct; 372(9647):1385-93. PubMed ID: 18823658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
    Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial.
    Malik RA; Williamson S; Abbott C; Carrington AL; Iqbal J; Schady W; Boulton AJ
    Lancet; 1998 Dec 19-26; 352(9145):1978-81. PubMed ID: 9872248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy.
    O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH
    J Hum Hypertens; 1993 Aug; 7(4):327-32. PubMed ID: 8410923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes.
    Keen H; Lee ET; Russell D; Miki E; Bennett PH; Lu M
    Diabetologia; 2001 Sep; 44 Suppl 2():S22-30. PubMed ID: 11587046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.
    Andersen NH; Knudsen ST; Poulsen PL; Poulsen SH; Helleberg K; Eiskjaer H; Hansen KW; Bek T; Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):96-9. PubMed ID: 12806591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients.
    Fogari R; Zoppi A; Corradi L; Lazzari P; Mugellini A; Lusardi P
    Br J Clin Pharmacol; 1998 Nov; 46(5):467-71. PubMed ID: 9833600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus.
    Henricsson M; Nilsson A; Janzon L; Groop L
    Diabet Med; 1997 Feb; 14(2):123-31. PubMed ID: 9047089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
    Sjølie AK; Klein R; Porta M; Orchard T; Fuller J; Parving HH; Bilous R; Aldington S; Chaturvedi N
    Diabet Med; 2011 Mar; 28(3):345-51. PubMed ID: 21309844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.
    Schrier RW; Estacio RO; Esler A; Mehler P
    Kidney Int; 2002 Mar; 61(3):1086-97. PubMed ID: 11849464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.